Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2011

Molecular Pathways Involved In Calcineurin Inhibitor
Nephrotoxicity In Kidney Allograft Transplants
Huong Nguyen
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Physiology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/2545

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

 Michelle Huong Nguyen
All Rights Reserved

2011

MOLECULAR MECHANISMS INVOLVED
IN CALCINEURIN INHIBITOR NEPHROTOXICITY
IN KIDNEY ALLOGRAFT TRANSPLANTS
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Physiology and Biophysics at Virginia Commonwealth University.

by

HUONG LE DIEM NGUYEN

Director: VALERIA MAS, Ph. D
ASSOCIATE PROFESSOR, DEPARTMENT OF SURGERY AND PATHOLOGY
DIRECTOR OF MOLECULAR TRANSPLANT RESEARCH LABORATORY
DIVISION OF TRANSPLANT

Virginia Commonwealth University
Richmond, Virginia
August 8th, 2011

ii

ACKNOWLEDGEMENTS

In world of research, one year is not necessary a long time but with the amount of
work and knowledge that I was able to gain after hands-on doing my own research
project under the direction by my advisor, Dr. Valeria Mas, it was a considerably
valuable time for me. Constantly inspired by the competency and diligent work by Dr.
Mas and the rest of our transplant research team, this learning experience taught me that
scientific research is not just about understanding phenomena and integrated knowledge
but to find passion in presented fact and experimental data.
I would like to thank Dr. Mas for her guidance and dedication. Her many
achievements and pioneering spirit in researching, especially in transplantation, and her
enthusiasm for science are the source of inspiration that encourages me to over come any
challenges, expand my knowledge, and become a better student. The more I get involved
with the state-of-art research technologies and the fascinating body of knowledge of
molecular biology we are doing in our transplant lab, the more I appreciate the fact that I
am part of this outstanding team.
Thanks Dr. Scian, for his enduring support and contribution to this project. I have
learned a great deal from his excellent research techniques as well as knowledge in
immunology. Thank you for being available to answer my questions and guide me
throughout my project. Lacey and Ryan! You guys are more than just fellow lab
members. Your friendship and nonstop encouragement made my lab experience exciting.
I am very grateful for the rest of my team Dr. Gehrau, Ngoc, Alex, Uzo, and Krystle. I
have enjoyed working with you all.

iii
I also would like to send my special gratitude to all of my committee members,
Dr. De Felice, Dr. Kuemmerle, Dr. Archer, and Dr. Dumur for their time and
consideration devoted to participate in my project. It is a great honor to have each one of
you served in my committee.
Lastly, I would like to thank my parents, my sister, my brother, and my favorite
person, Hyun Suck, for setting forward examples of aspiring hard work and success.
Thank you for your unconditional love and endless faith in me. I was able to make it this
far because you have walked along my side on this long and challenging path. I love you
all.

iv

TABLE OF CONTENTS

Acknowledgements ...........................................................................................................................ii
List of Tables ....................................................................................................................................vi
List of Figures ...................................................................................................................................vii
List of Abbreviations ........................................................................................................................viii
Abstract .............................................................................................................................................x
Chapter I: Introduction ......................................................................................................................1
I. An Overview of Kidney Transplantation ...........................................................................1
II. Immunology in Kidney Transplantation ...........................................................................2
III. Clinical Diagnosis of Renal Allograft Pathology ............................................................6
IV. Calcineurin Inhibitors as Immunosuppressive Therapeutic Agents ................................7
V. Calcineurin Inhibitor Nephrotoxicity ................................................................................14
VI. Challenges in Drug Therapeutic Monitoring and Management ......................................18
VII. Study Rationale ..............................................................................................................20
VIII. Specific Aims ................................................................................................................21
Chapter 2: Research Materials and Methods .....................................................................................22
I. Patient and Sample Selection ............................................................................................22
II. RNA Isolation from Kidney Tissues ................................................................................22
III. Quantity Measurement and Quality Assessment of Isolated RNA ..................................24
IV. Real-time PCR ................................................................................................................25
V. Description of Microarray Assay ......................................................................................27
VI. Microarray Data Analysis ...............................................................................................29
VII. Gene Annotation ............................................................................................................29
VIII. Validation of Microarray Data .....................................................................................30
Chapter 3: Results ..............................................................................................................................32
I. Patient Demographics and Clinical Values ........................................................................32
II. Microarray Results ...........................................................................................................33
III. Biological Networks and Pathway Analysis in CNI Population ....................................34
IV. Biological Function and Toxicology Profile of CNI and IF/TA .....................................41
V. Differential Gene Expression Profiling ............................................................................43

v
VI. Q-PCR Validation of Microarray Data ............................................................................46
VII. Q-PCR Validation in an Independent Set of Samples ...................................................47
Chapter 4: Discussion .......................................................................................................................51
References .........................................................................................................................................59

vi
List of Tables
Page
Table 1: Classification of Allograft Rejection ......................................................................................3
Table 2: Patient Sample Demographics and Available Clinical Values ............................................32
Table 3: Histological Evaluation of Kidney Biopsies Using Banff ’07 Update ................................33
Table 4: Biological Networks Ranked By Score In CNI Tissues .......................................................35
Table 5: Criteria for Selecting Genes For Validation ........................................................................43
Table 6: Candidate Gene With Significant Expression In CNI Population ........................................44
Table 7: Candidate Genes With Significant Expression In CNI And IF/TA ......................................45
Table 8: Characteristic Genes For CNI Nephrotoxicity .....................................................................46
Table 9: T-test Of Genes Used IN Confirmation ................................................................................46
Table 10: Relative Fold Changes of Gene Expression .......................................................................47
Table 11: Pearson’s Correlation Coefficient Values .........................................................................47
Table 12: T-test Of Genes in Validation .............................................................................................48
Table 13: Relative Fold Changes of Validated Genes ........................................................................48

vii
List of Figures
Page
Figure 1: Calcineurin/NFAT Signaling Pathway ...............................................................................10
Figure 2: An Overview of Taqman Protocol .....................................................................................26
Figure 3: Basics of 5’ Nuclease Assay ...............................................................................................27
Figure 4: Venn Diagram .....................................................................................................................34
Figure 5: Interaction Network 4 in CNI vs. NA .................................................................................38
Figure 6: Interaction Network 8 in CNI vs. NA .................................................................................39
Figure 7: Top Canonical Pathway in CNI vs. NA ..............................................................................40
Figure 8: TGF- Signaling Pathway ...................................................................................................41
Figure 9: Comparison in Biological Function of CNI vs. IF/TA ........................................................42
Figure 10: Comparison in Toxicology Function of CNI vs. IF/TA ....................................................43
Figure 11: Fold Change in Gene Expression of CXCR4, RGS1, and TGIF1 ....................................48

viii

List of Abbreviations
C
ACR
AMR
AP1
AR
BAD
Bcl2
Ca2+
CD4
CD8
cDNA
CN
CNA
CNB
CNI
CsA
Ct
CXCR4
CYP
DARPP 32
DNA
Elk 1
EMT
ESRD
FFPE
FK506
FKBP12
GAPDH
GFR
HLA
Hsp25
IF/TA
IL2
IL4
IPA
IPKB
JNK
L
MAP 2
MEF2
MGB
MHC
miRNA

Degree Celsius
Acute Cellular Rejection
Antibody-Mediated Rejection
Activator Protein 1
Acute Rejection
Bcl- X L /Bcl-2-associated death promoter
B-cell lymphoma 2
Calcium ion
Cluster of Differentiation 4
Cluster of Differentiation 8
Complementary DNA
Calcineurin
Calcineurin subunit A
Calcineurin subunit B
Calcineurin Inhibitor
Cyclosporine A
Critical Threshold
Chemokine (C-X-C motif) Rceptor 4
Cytochrome P450
Dopamine And cAMP Regulated Neuronal Phosphoprotein
Deoxyribose Nucleic Acid
ETS-like Transcription Factor 1
Epithelial Messenchymal Transition
End-Stage Renal Disease
Formalin-fixed, Paraffin-Embedded
Tacrolimus
FK-Binding Protein 12
Glyceraldehyde 3-Phosphate Dehydrogenase
Glomerular Flow Rate
Human Leukocyte Antigen
Heat Shock Protein 25
Interstitial Fibrosis and Tubular Atrophy
Interleukin 2
Interleukin 4
Ingenuity Pathway Analysis
Ingenuity Pathways Knowledge Base
Jun- N Terminal Kinase
Litter
Microtubule Associated Protein 2
Myocyte Enhancer Factor 2
Minor Groove Binder
Major Histocompatibility Complex
Micro RNA

ix
mTOR
NA
NFAT
NFQ
NFB
NO
NTC
PKA
PP1
Q-PCR
RGS1
RNA
rRNA
RT-PCR
TGF
TGIF1
TNF
Treg
UNG

Mammalian Target of Rapamycin
Normal Allograft
Nuclear Factor of Activated T-cells
Non-fluorescent Quencher
Nuclear factor kappa-light-chain-enhancer of activated B
Nitric Oxide
No Template Control
Protein Kinase A
Protein Phosphatase 1
Real-time Polymerase Chain Reaction
Regulator of G-Protein Signaling 1
Ribose Nucleic Acid
Ribosomal RNA
Real-Time Polymerase Chain Reaction
Transforming Growth Factor 
TGF-induced Factor Homeobox 1
Tumor Necorsis Factor
Regulatory T cell
Uracil-N-Glycosylase

x

ABSTRACT

MOLECULAR MECHANISMS INVOVLED IN CALCINEURIN INHIBITOR
NEPHROTOXICITY IN KIDNEY ALLOGRAFT
By Huong Le Diem Nguyen, M.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Physiology at Virginia Commonwealth University.
Virginia Commonwealth University, 2011.
Major Director: Valeria Mas, Ph.D.
Associate Professor, Department of Surgery and Pathology
Director of Molecular Transplant Research Laboratory, Division of Transplant

Calcineurin inhibitors (CNI), cyclosporin A and tacrolimus, are potent
immunosuppressive agents but induce toxicity causing damages and graft dysfunction in
kidney transplant recipients. They also have been suggested to contribute to late-term loss
of graft, which is depicted by interstitial fibrosis and tubular atrophy (IF/TA). Even with
emerging insights on mechanism of CNI nephrotoxicity, prevention and treatment of this
toxicity remain a major clinical challenge due to its low dose-toxicity correlation, a
difficulty in establishing a differential diagnosis, and varying individual susceptibility.
We hypothesize that CNI nephrotoxicity follows distinct disease pathways and is
characterized by significant gene signatures that differentiate it from other conditions.
Moreover, we postulate that CNI-induced toxicity profiles contribute to the IF/TA
signatures.
Microarray analysis and gene annotation were done on the study database
included of tissues diagnosed with CNI nephrotoxicity (n = 9), interstitial fibrosis/tubular
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atrophy (IF/TA, n=10), and normal function allografts (NFA, n = 8). All samples were
histologically classified based on the revised Banff ‘07 criteria for renal allograft
pathology. Top-scored biological networks in CNI tissues were related to metabolic
disease, cellular development, renal necrosis, apoptosis cell-death, immunological
disease, inflammatory disease, and many others. Canonical pathway analysis emphasized
oxidative stress response mediated by NRF2 and various cell-death signaling pathways
including 14-3-3 signaling pathway, p53 signaling pathway, and TGF- signaling
pathway.
Profiling of characteristic gene expression patterns was done based on their
statistical significance and biological relevance to the unique pathology of CNI
nephrotoxicity. Three differentially expressed genes RGS1, CXCR4, and TGIF1, which
showed good correlation between microarray data and real time-PCR, were validated in
an independent set of sample tissues. Even though only RGS1 gene expression level was
statistically significant between CNI group and normal function allograft, relative fold
changes of both RGS1 and CXCR4 showed a significant up-regulation associated with
the pathological groups (CNI and IF/TA), when compared to normal function allograft.
We did not, however, find any association between the expression of TGIF1 in either
CNI group or IF/TA group.

CHAPTER 1: INTRODUCTION

I. An Overview of Kidney Transplantation
1. Prevalence and Current Trends
To date, approximately 23 million people, more than 11.5% of the U.S. adult
population, are suffering from chronic kidney disease, with high risk of having kidney
failure, end-stage renal disease (ESRD), and even mortality (1,2). Kidney transplantation
has been the therapy of choice for patient with ESRD for decades. Over the past 10 years,
there is an improvement in short-term patient and graft survival due to advances in
surgical techniques as well as clinical immunology in transplantation (2). According to a
study on kidney transplantation in the U.S. from 1999 to 2008, unadjusted patient
survival rates at 5 years after transplant were 91% for recipients of living donor (LD)
kidneys, 84% for non-expanded donor criteria deceased donor (non-ECD DD) kidneys,
and 72% for expanded donor criteria (ECD) kidney transplants (3). Unadjusted graft
survival at 5 years post-transplantation followed a similar trend with 81% for LD, 72%
for non-ECD, and 57% for ECD transplants (3).
Despite this promising short-term outcome, long-term survival rate of kidney
transplant recipients is poor. One of the main reasons is the growing disparity between
the number of patients waiting for organs and the number of organs available for
transplant (4). In fact, 94,293 patients are registered on the national waiting list while the
organs available for transplant are 13,522 in 2010 and 1114 in 2011 according to the
registration database reported by U.S. Department of Health and Human Services (5).
This also reflects on 40% increase of death on the waiting list for a kidney transplant (3-
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5). Other factors that limit the long-term survival rate of kidney transplant recipients are
rejection, infection, drug-related toxicities, and many others post-transplant
complications.
2. Changes in Kidney Donation and Utilization
Analyses on kidney transplantation in the U.S. indicate an overall increasing trend
in transplant candidate selection, preparation, and donor kidney utilization (6). Transplant
from living kidney donors, either related or unrelated, has been motivated with ethical
justification of steadily high survival rates among recipients even when compared with
those from deceased donors with equivalent degrees of human leukocyte antigen (HLA)
matching (4,6).
The standards of transplantable organs harvested from deceased donors were also
modified within the past decades in attempt to expand the kidney pool for transplant (6).
Previous deceased donor organs which were deemed to be “marginal” due to advanced
age, a history of hypertension or diabetes mellitus, prolonged cold-ischemia time, or
elevated serum creatinine concentration at the time of organ harvesting are now
categorized into a separate kidney transplant waiting list for recipients willing to accept
organs based on “expanded donor criteria” (6-8).
II. Immunology in Kidney Transplantation
1. Immune Response to Kidney Allograft
As kidney transplantation usually involves placement of kidney allografts of
immunologically different individuals, transplant recipients‟ immune response is a major
determinant of overall outcome of the transplant. After allogenic human leukocyte
antigens are presented for recognition by T cells, either via direct or indirect
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presentations, recipient T and B cells provoke various effector mechanisms of the defense
systems to fight against foreign donor antigens (8,9). As this implies, the larger the
number of HLA alleles that are matched between the donor and recipient, the better the
graft survival, especially in the first year after transplantation (9).
2. Pathogenesis of Kidney Transplant Rejection
Table 1 below summarizes the experience of rejection based on histopathologic
patterns in renal allograft.

Types

Table 1: Classification of Allograft Rejection
CLASSIFICATION OF REJECTION
Time Course
Pathological Features

Hyperacute

Minutes to hours

Acute

Weeks to months
(varied)

Chronic

Months to years

Complement activation
Endothelial damage
Inflammation thrombosis
Parenchymal cell damage
Interstitial inflammation
Endothelialitis
Arteriosclerosis
Intimal smooth muscle
proliferation
Vessel occlusion

Hyperacute Rejection. The presence of donor enthothelial antigens within
minutes to hours after host blood vessels are anastomosed to graft vessels triggers
antidonor antibodies (8). This activates the complement system resulting in thrombotic
occlusion of the graft vasculature, which can lead to an irreversible ischemic change in
the kidney allograft (8). Hyperacute rejection, thus, can cause immediate or near
immediate loss of graft function (8-10). Patho-morphology of this type of rejection is
characterized by interstitial hemorrhage, microthrombosis, and inflammation (9).
Fortunately, in the modern era of transplantation, the risk of hyperacute rejection is
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preventable with molecular assays such as fluorescence-activated cell sorting cross-detect
levels of these antibodies (10).
Acute Rejection. Acute rejection remains a major complication after kidney
transplantation and a major risk factor for chronic allograft dysfunction (8,9,11). Acute
rejection mediated by T-lymphocytes is known as acute cellular rejection (ACR) and is
due to accumulation of mononuclear cells (mostly T cells and macrophages) in the
interstitium, followed by inflammation of tubules and sometimes of arteries (12). The
precise mechanisms are yet uncertain but there are two proposed theories on ACR. The
first theory hypothesizes that cell-mediated cytotoxicity of parenchymal cells is due to the
participation of CD8+ T cells, while the other surmises that local cytokine release is
mediated by CD4+ T cells (8,9). CD8+ class I reactive T cells kill target cells through
perforin and granzyme B, and through Fas/FasL cytolytic pathways (8,9). Cytokines may
act directly on tubular cells or indirectly via effects on endothelium and vascular supply.
The role of regulatory T cells during ACR continues to be characterized (8).
While activation of antibody-mediated immune response toward HLA class 1 and
class 2 antigens prior to the transplantation is the underline mechanism of hyperacute
rejection, arrival of reactive antibodies post-transplantation is the process of acute
rejection, or to be more specific, antibody-mediated rejection (AMR). The pathologic
patterns that differentiate this form of acute rejection from hyperacute rejection are
consequent transmural necrosis of graft vessel wall and acute inflammation (9). Renal
injuries caused by antibody-mediated rejection can be detected with evidence of focal
ischemia, severe injury to the endothelial cells of glomeruli and small arterioles in the
graft, and diffuse intravascular coagulation (9,12).
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Chronic Rejection. Several episodes of acute rejection and increasing severity of
rejection lead to development of chronic allograft nephropathy, which is depicted by
interstitial fibrosis and tubular atrophy (IF/TA) (9,13). IF/TA emphasizes a progressive
deterioration of renal function, worsening hypertension, proteinurea, and eventually graft
loss (13,14,15). Although it has been emphasized that immunological and hypertensive
injuries as well as immunosuppressant-related toxicities contribute to the progression of
IF/TA, the specific pathogenesis is poorly understood (14,15). A well-documented study
on histological damages to transplanted kidney shows that early tubulointerstitial damage
correlates with immunologic factors, including severe acute rejection and persistent
subclinical rejection in the addition to ischemia–reperfusion injury (16). Later damage of
chronic allograft nephrotoxicity is characterized by progressive arteriolar hyalinosis,
ischemic glomerulosclerosis, and further interstitial fibrosis associated with long-term
calcineurin-inhibitor nephrotoxicity (13-17).
3. Prevention and Treatment of Allograft Rejection
The major strategy of kidney transplantation immunology is, therefore, to reduce
immunogenicity of allograft and to minimize alloantigenic difference between donor and
recipients. The current standard of practice in preventing acute rejection and graft loss in
all kidney transplant recipients involves a lifelong immunosuppression therapy. In fact,
the current standard regimen in most transplant programs in the U.S. consists of induction
with IL-2R or  lymphocyte-depleting antibody and maintenance with a calcineurin
inhibitor in combination with mycophenolate mofetil or sirolimus and long-term
prednisone therapy (18). Calcineurin inhibitors (CNI) that are employed in clinical
practice in the past 30 years are cyclosporine A (CsA) and Tacrolimus (also known as
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FK506). The mechanisms and toxicities induced by calcineurin inhibitors in kidney
allograft of transplant recipients are the focus of this study and will be discussed in great
details in the following sections of this chapter.
III. Clinical Diagnosis of Renal Allograft Pathology
In addition to traditional clinical parameters such as serum creatinine level,
estimated glomerular flow rate (GFR), albuminuria and etc., the diagnostic system
evaluating level of pathophysiological disturbances on the transplanted kidney allograft
largely relies on biopsy-based histological evidence (19). The current international
standard classification of renal allograft pathology is the Banff schema. Originated in a
meeting held in Banff, Canada in 1991, the Banff Working Classification defines
pathologic criteria of rejection and characterizes renal allograft pathology into five
categories: 1-antibody-mediated rejection, 2-suspicious of acute rejection, 3-acute
rejection, 4-chronic sclerosing allograft nephropathy, and 5-other changes not considered
due to rejection (20). The Banff criteria for rejection are reviewed and updated every two
years. The latest version was updated in 2007.
Diagnosis of renal allograft pathology via the Banff criteria in clinical practice,
however, is complicated by many factors such as subclinical damages, borderline
changes, tissue fixation, and tissue structural heterogeneity (19, 20). Previous studies on
the reproducibility of the Banff schema, via kappa statistical tests, which corrects for the
agreement due by chance, show limited inter- and intra-observer agreement among
pathological reports for diagnosing and grading of rejection (20). This, however, leaves
room for molecular biological approaches to introduce the objective techniques of
microarrays.
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Microarray technology is based on the principle of complementary, singlestranded, nucleic acid sequences forming double-stranded, nucleic acid sequences
forming double-stranded hybrids (22). The high-throughput survey of genes empowered
by microarray allows many issues such as kidney structural heterogeneity, development,
and fixation, and certain treatments in the expression of immunoreactive proteins can be
simultaneously addressed (23). Global gene-to-gene interaction in biological context
indicated in microarray data can be used to characterize gene expression-regulation in
post-transplant patients who have received various immunosuppressants (23,24). The
behavior of genes can be applied as potential markers for monitoring rejection
susceptibility in biopsy specimens or utilized in monitoring gene expression changes in
response to therapeutic treatments and guide clinical trials (24). In this context, we have
implemented the microarray technique to test our hypothesis and quantitatively profile a
set of genes with differential expression patterns associated with calcineurin inhibitor
nephrotoxicity.
IV. Calcineurin Inhibitors as Immunosuppressive Therapeutic Agents
1. Clinical Administration
In the early 1980s, cyclosporine A was the first approved calcineurin inhibitor for
clinical practice. It is a cyclic undecappeptide produced by fungus Hypocladium inflatum
gams (25). Tacrolimus, a macrolide lactone, extracted from fungus Streptomyces
tsukubaensis was later discovered and introduced into the class of calcineurin inhibitors
(26). Since the institution of calcineurin inhibitors, the rate of acute rejection has been
reduced dramatically reflecting improved short-term survival rates of allograft and kidney
transplant patients.
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However, because of their severe side effects, the use of CsA and FK506 has been
restricted to serious clinical situations such as the prevention of organ transplant rejection
(25,26). Currently, about 94% of kidney transplant recipients are discharged with a
calcineurin inhibitor-based immunosuppressive regimen (26). The major toxic effects
associated with the use of these drugs are nephrotoxicity, hypertension, diabetes,
neurotoxicity, and gastrointestinal disorders (25-27). Chronic exposure to CNI is also
believed to contribute to the development of chronic allograft dysfunction –IF/TA, the
major cause of graft loss in kidney transplantation (27).
Investigations on crystal structures of cyclosporine and tacrolimus reveal that they
are unrelated in structures, interact with distinctive cellular receptors, but exert the same
pharmacological effects on immune system in transplanted allograft (25,28). In vitro
studies on human cultured CD4 helper T lymphocytes have demonstrated that tacrolimus
is superior to cyclosporine in selectively inhibiting the secretion of various cytokines,
including IL-2 (28). Comparative studies on CsA and FK506, furthermore, showed
different toxicology profiles (27). It was pointed out that tacrolimus is more likely
associated with diabetes and neurotoxicity but less with hypertension, dyslipidaemia than
cyclosporine (28). Yet studies on nephrotoxic side effects, or the direct toxicity on kidney
allograft of transplant patients, indicated that these toxicities are comparable between
patients treated with tacrolimus and patients treated with cyclosporine (28).
2. Calcineurin/NFAT Signaling Pathway in T cells
Analog studies of cyclosporine and tacrolimus profoundly elucidate their
immunosuppressive potency via selective inhibition of calcineurin (CN), a cellular
serine-threonine phosphatase. CN is composed of a catalytic subunit calcineurin A
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(CNA) and a regulatory subunit calcineurin B (CNB). Molecular analyses of calcineurin
subunits depict that the N-terminal region of CNA houses its catalytic activity while the
C-terminal region contains the binding sites for calcineurin B and calmodulin (25,29).
The binding between the two subunits (A and B) leads to blockade of the CNA active site
and results in auto-inhibition of calcineurin.
Calcineurin‟s activity is tightly regulated by the level of calcium in cells via the
interaction between binding of calmodulin/calcium and calcineurin regulatory subunit. In
resting cells, with low intracellular Ca2+ level, calcineurin is in inactive form, as CNA
and CNB remain tightly associated (25,29). In stimulated cells, sustained increase in
cellular calcium allows the interaction between this ion and calmodulin and triggers a
conformational change in the regulatory domain of subunit A. It results in the reversibly
displacement of the auto-inhibitory sequence from the active site and induction of CN‟s
enzymatic activity (29).
Immunological properties of calcineurin primarily rely on its direct role in the
nuclear factor of activated T-cells (NFAT) signaling pathway, an important signaling
pathway required for T cell proliferation and activation (Figure 1). NFAT is a family of
transcription factors, which regulate a diversity of genes in immune cells including
cytokines, cell-surface receptors, and chemokines (29). Calcineurin binds directly to the
N-terminal regulatory domain of NFATs, which is extensively phosphorylated in resting
cells (25,29). Under normal conditions, these phosphorylated residues favor a
conformational state that results in the masking of the nuclear localization sequences
(NLS) necessary for NFAT translocation to the nucleus (28,). Upon an immune
response, there is a sustained influx of calcium ions into T cell and subsequently activates
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calcineurin via the mechanism described above. This protein phosphatase removes
appropriate phosphate groups on NFAT proteins and reveals their signal sequence that
allows these transcription factors to enter the nucleus and induce transcription of IL-2,
IL-4, and TNF, which are necessary for T cell to proliferate and be activated (24,28).

Figure 1: Calcineurin/NFAT Signaling Pathway (30)
Calcineurin plays a critical role in governing the process of rejection because IL-2,
in particular, is a powerful inflammatory catalyst implicated in allograft rejection (31).
The amount of IL-2 produced by the helper T cells significantly influences the extent of
the immune response (29,31). As described previously, the genes that determine the
rejection or acceptance of tissue grafts are present in a locus on human leukocyte antigen.
The central event in the initiation of an immune response is the recognition of the peptide
in HLA by the T-cell receptor. Cyclosporine and tacrolimus inhibits calcineurin, thus
preventing T-lymphocyte activity in response to exposure to the peptide from the human
leukocyte antigens (31).
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Recent studies on the function of calcineurin also reveal that this phosphatase has
other physiological substrates besides NFAT transcription factors. These include
inhibitor-1, an endogenous inhibitor of protein phosphatase 1 (PP1); DARPP- 32, a
dopamine- and cAMP-regulated phosphoprotein that also inhibits PP; the microtubuleassociated proteins tau factor, MAP-2, and tubulin; a calmodulin binding protein named
neuromodulin; the regulatory RII subunit of cAMP dependent protein kinase (PKA); NO
synthase; the transcription factors MEF2 and Elk-1, components of the synaptic
endocytic machinery such as dephosphins, the heat shock protein hsp25, and the Bcl2
family member BAD (25,31). These findings indicate that inhibitory activity of CsA and
FK506 can cause effects on a variety of canonical pathways, molecular networks, and
biological functions.
3. Mechanism of Action of Calcineurin Inhibitors
Although calcineurin is distributed through out the body and highly conserved
among different organisms, T cells are sensitive to calcineurin inhibitors because they
express a high level of this protein (25,32). Due to their hydrophobic nature, calcineurin
inhibitors diffuse across the plasma membrane to interact with their cytoplasmic
receptors. Cyclosporine A binds with high affinity to cyclophilin and tacrolimus binds to
FK-binding protein 12) (24-30). Cellular receptors of CNI are generally known as
immunophilins, which are ubiquitously expressed proteins that possess peptidyl-proline
cis-trans isomerase activity, significant for protein folding and complex stabilization (28,
30). Via analogs studies, binding of CsA and FK506 to their receptors blocks the prolyl
isomerase activity of these proteins, but this inhibition is unrelated to the
immunosuppressive action of these drugs (24). The drug and receptor complexes,
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however, inhibit calcineurin phosphatase activity by blocking the access of the protein
substrates to the active site of this enzyme (24).
Via the mechanism involving NFAT signaling pathway, reviewed above, the
blockade of the calcineurin/NFAT pathway appears to be the major mechanism of
immunosuppression mediated by cyclosporine and tacrolimus. But other transcription
factors involved in lymphocyte activation such as NFkB and AP1 are partially affected
by these drugs (24,25,32). However, unlike NFAT, the inhibitory action of CsA and
FK506 on NFkB and AP1 appears to be indirect. Another alternative mechanism of
immunosuppression by CNI may involve inhibition of JNK and p38, through a
calcineurin- independent pathway, but the upstream signaling components targeted by the
drugs in this inhibitory pathway remain to be unclear (24).
4. Pharmacokinetics & Pharmacogenetics of Calcineurin Inhibitors
The pharmacokinetic parameters underline a narrow therapeutic window and a
large variability in inter-individual response (33). After intestinal absorption, calcineurin
inhibitor is primarily distributed to erythrocytes and is approximately 99% protein bound
to both α-acid glycoprotein and albumin (25,34). Cytochrome P450 (CYP) 3A4 and some
CYP3A5 and P-glycoproteins are important for the process of eliminating of CNI. Pglycoprotein pumps CNI out of the cell into the intestinal lumen, where metabolism of
CNI is done by CYP3A4 (34).
Polymorphism or genetic variations in CYP3A4 and CYP3A5 have been reported
to affect the pharmacokinetics, specifically, dosing and serum concentrations of
calcineurin inhibitors in kidney transplant patients (34,35). It has elucidated that
CYP3A51 carriers have a tacrolimus clearance rate of 25– 45% greater than that of
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CYP3A53 homozygotes, with proportional dosing needs to maintain adequate
immunosuppression (35). Since inadequate immunosuppression directly leads to graft
rejection, understanding the contribution of polymorphisms in pharmacokinetics of CNI
may be helpful in determining an appropriate starting dosage, rapidly achieving adequate
immunosuppression, and ultimately improving the outcome of renal transplantation
(35,36). Clearance range of tacrolimus is from 15 - 70 L per hour (36). For cyclosporine,
a median apparent clearance is about 29 L per hour with a range from 20 - 50 L per hour
(36). The dosage can be reduced during maintenance therapy, depending on clinical
assessments of rejection and tolerability for each patient (36).
5. Calcineurin Inhibitor Adverse Drug Effects
The adverse effects associated with calcineurin inhibitor administration adds to
the range and complexity of the issues surrounding post-transplantation complications in
transplant recipients as this trades the morbidity and mortality of organ failure for the
risks of infection, cancer, and toxicities. Three main underline side effects associated
with calcineurin inhibitors frequently observed in kidney transplant patients are diabetes
mellitus, hypertension, and nephrotoxicity.
Calcineurin Inhibitor-Induced Diabetes Mellitus. It has been demonstrated that
steroid-based drug regimens increase the risk and actually contribute to hyperglycemia
and development of post-transplant diabetes mellitus, resemblance to type 2 diabetes
(37). In the case of calcineurin inhibitor-based therapy, there is a potentially direct impact
of cyclosporine and tacrolimus on the insulin gene expression at a transcriptional level.
Studies on calcineurin/NFAT signaling pathway in normal and pathologic -cell function
show that calcineurin inhibitor, specifically tacrolimus, induce -cell apoptosis and
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therefore suppress expression of insulin (38).
Calcineurin Inhibitor-Induced Hypertension. Since calcineurin inhibitors disturb
the balance of vasoconstriction and vasodilation affecting homeostasis and blood
pressure, they cause a decrease in glomerular filtration rate and enhanced sodium
reabsorption in the renal tubules (39,40). The mechanism involves an increase in intrarenal renin expression, local endothelin-1, and thromboxane but a reduction in intra-renal
nitric oxide and prostaglandin (39,40). Alternative mechanisms are via activation of the
sympathetic nervous system and disturbance of sodium and water retention (41).
Calcineurin Inhibitor-induced Nephrotoxicity. Calcineurin inhibitors are thought
to produce nephrotoxicity, which alters the kidney function and architecture. In
particular, chronic exposure to CNI induces macrophage infiltration and interstitial
fibrosis on kidney biopsy (24,34,41). Hypertension and adverse drug effects are tightly
associated, so the mechanisms involved in cyclosporine- induced hypertension could also
influence its adverse effects on the kidney (34,41).
V. Calcineurin Inhibitor Nephrotoxicity
Nephrotoxicity is observed not only in transplanted kidneys but also in native
kidneys in patients who receive CNI treatment after other organ transplant or in patients
suffering from autoimmune diseases (24,34,41). A well-documented research on longterm assessment of kidney transplant patients treated with cyclosporine (26) reports the
progression of nephrotoxicity events in 888 biopsies collected from 99 transplant
recipients. As early as the first year after transplantation, more than 50% of these biopsies
show signs of toxicities altering kidney‟s architecture and function. After 10 years,
virtually all biopsies were diagnosed with chronic cyclosporine-induced nephrotoxicity.
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Previous studies on toxicology profile of CNI indicate that allograft treated with
tacrolimus and cyclosporine share the same nephrotoxic side effects (41).
1. Acute Nephrotoxicity
Acute nephrotoxicity induced by calcineurin inhibitors is characterized by
hemodynamic-mediated insults to nephrons of kidney allograft, which are reversible with
dose reduction or CNI withdrawal. The major signs of acute nephrotoxicity include a
decrease in glomerular flow rate, acute arteriolopathy, tubular vacuolization, and
thrombotic microangiopathy (41). At molecular level, calcineurin inhibitors alter kidney
hemodynamic via disturbance of the balance between vasoconstrictive and vasodilator
mediators.
There is an increase in endothelin, a potent vasoconstrictor (41). The mechanism
underlying CNI-induced increase in endothelin is still uncharacterized, yet, endothelin
has been found widely released in the kidney and vascular beds of allograft treated with
calcineurin inhibitors (34,41). Activation of renin-angiotensin system (RAS),
furthermore, causes arteriolar vasoconstriction by direct effect on juxtaglomerular cells
and indirect effect on renal vasculature (41). Through the action of angiotensin II, RAS
activation causes an overall rise in renal vascular resistance. Vasoconstrictory effect of
angiotensin II, mediated by calcineurin inhibitor administration, is also seen in smooth
muscle cells by influences on intracellular calcium stores, smooth muscle cell phenotypic
maintenance, and contractility (25,41).
As action of calcineurin inhibitors also causes inhibition of NO synthesis, this
results in endothelium-dependent NO-mediated renal vasodilation (24,41). This is
believed as the main mechanism of cyclosporine-induced hypertension and decreased
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GFR (25,41). Formation of free radicals and activation of the sympathetic nerve could
also contribute to the increase renal vascular resistance and secondarily decreased GFR.
In tubular cells, nephrotoxicity induces enlargement of the endoplasmic reticulum
and increased lysosomes, resulting in isometric vacuolization of the tubular cytoplasm, a
morphologic hallmark of acute calcineurin inhibitor nephrotoxicity (24,25,26,34,41).
However, vacuolization is also observed in renal ischemia or tubular epithelial injury
cause by intravenous administration of hyperosmotic fluids but in absence of renal
dysfunction (41). It is also found in allograft treated with steroid and azathioprine (41).
Some evidence also indicates formation of inclusion bodies in the tubular cytoplasm,
which represent giant mitochondria and autolysomes, possibly due to ischemic injury
(41). Thrombotic microangiopathy marks evidence of acute nephrotoxicity and
underlying endothelial injury secondary to vasoconstriction-associated ischemia, in
addition to an increase platelet aggregation and activation of pro-thrombotic factors
(24,41).
2. Chronic Nephrotoxicity
Chronic calcineurin inhibitor nephrotoxicity is characterized by irreversible
damages to the renal architecture and function. Long-term exposure to cyclosporine and
tacrolimus show the same spectrum of induced toxicities in the vessels, tubulointertitium, and glomeruli. The hallmark patho-morphologies of chronic calcineurin
inihibitor nehphrotoxicity include 1-arteriolar hyalinosis, 2-thickening and fibrosis of
Bowman‟s capsule and focal segmental or global glomerular sclerosis, and 3-tubular
atrophy and interstitial fibrosis (41). Arteriolar hyalinosis occurs when nodular hyaline
deposits in the media of afferent arterioles to replace of necrotic smooth muscle cells.
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Deposition of these focal lumpy proteins at the periphery of the wall of afferent arterioles
causes narrowing of the vascular lumen.
Allografts of kidney transplant recipients treated with calcineurin inhibitors also
show evidence of glomerular injury such as global glomeruloslecorsis and secondary
gomerular ischemia (41). Global glomerulosclerosis is resulted from sever arteriolar
hyalinosis and arteriolopathy. Secondary glomerular ischemia obversed in calcineurin
inhibitor nephrotoxicity has similar profile as that seen in diabetes mellitus (24,34,41).
Arteriolopathy and narrowing of the arteriolar lumen are believed to be the major
contributors to the development of calcineurin inhibitor induced interstitial fibrosis and
tubular atrophy. Local ischemia of the tubulo-interstitial compartment leads to formation
of free radicals and reactive oxygen species as well as consequences of cellular injury and
apoptosis (41). The proposed mechanisms indicate directly activation of apoptosis gene
by calcineurin inhibitors in tubular and interstitial cells (41). These mechanisms are
hypothesized to underlie the contribution of calcineurin inhibitor nephrotoxicity to the
development of IF/TA.
Another major mechanism, which is believed to complicate chronic CNI
toxicities, is induced epithelial mesenchymal transition (EMT) due to up-regulation of
TGF (25,41). TGF promotes degradation while reducing production of extracellular
matrix proteins. EMT is a multistep process in which renal tubular epithelial cells lose
their cell morphology and acquire new characteristic features of mesenchyme. Loss of
cell-cell adhesion through down-regulation of E-cadherin destruction of basement
membrane seen in EMT causes cell migration and invasion.
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Some of these effects could be independent of calcineurin inhibition, because the
binding of these drugs to different immunophilins could also interfere with their
physiological functions (24). In this regard, CsA has been shown to inhibit the opening of
mitochondrial permeability transition pore, which is involved in cell death, by binding to
cyclophilin-D and thus removing this immunophilin from the complex pore (42). It is
possible that CsA/FK506-dependent toxicity may result from interference of the drugs
with calcineurin substrates or target genes of NFAT in non-immune cells, and there are
several CN-regulated processes that may be important in this regard (24,41). These kinds
of interference may underlie the toxic effects of CsA and FK506 on the physiological
functioning of kidney.
VI. Challenges In Drug Therapeutic Monitoring And Management
Both of these immunosuppressive agents have a narrow therapeutic window and
low correlation between dose-toxicity (35). This explains why plasma level of CNIs fails
to predict either rejection or toxicity (41). Clinical differential diagnosis of CNI faces
further challenges as responses to drug absorption, distribution, metabolism, and
elimination of CsA and tacrolimus are highly varied not only among individuals but also
within the body. Pharmacokinetic and pharmacogentic studies of calcineurin inhibitors
indicate a variability profile with high inter-individual difference. Genetic predisposition
of cytochromic enzymes CYP3A4 and CYP3A5, which are responsible for metabolism of
CNIs in the intestine and the liver, implies varying metabolic capacity accompanied with
sources of dysfunction or failure contributed by induced nephrotoxicity (36). As a result,
it undermines the effectiveness of the current routine therapeutic monitoring effort and
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suggests the need of developing an efficient system of clinical assessment of toxicities in
CNI treated patients.
Histological findings in acute nephrotoxicity indicate isometric vacuolization of
the tubular cytoplasm, smooth muscle cell degeneration, and thrombotic microangiopathy
(24). Yet, these morphological diagnoses have poor reproducibility and many of these
conditions have been seen as secondary to other toxicity and injury in renal allograft such
as acute immunology-mediated rejection (41). Due to the direct involvement of T-cell
signaling pathway in their mechanism of action, CNI shares many common mediators
with acute cellular rejection (41). Microscopic evidence shows that thrombotic
microangiopathy due to cyclosporine toxicity, moreover, looks morphologically identical
to that seen with humoral rejection in kidney transplantation (43).
For the past 30 years, cyclosporine A and tacrolimus are known as the most
potent, specific and well-known inhibitors of calcineurin (24). Other classes of
immunosuppressants used in kidney transplantation beside calcineurin inhibitors are
corticosteroids, antimetabolites (mycophenolate mofetil, mycophenolate sodium, and
azathioprine), and target-of-rapamycin-inhibitor (mTOR) (sirolimus and everolimus).
They have been the targets of many researches in comparison to CNI in term of drug
efficacy for sufficient immunosuppression and undesirable drug-induced toxicities.
Despite the apparent affects, they did not protect allograft from insults and injury
in long-term exposure (44-52). Among them, mTORs show the most severe adverse
effects, including hypertriglyceridemia, thrombocytopenia, and leucopenia besides
proteinuria (49). Without long-term validation in sustaining protective immune response
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and adequate suppression of the residual response to the graft, there is a lack of consistent
results on literature in regards of finding a substitution for CNI in kidney transplantation.
In other words, it is essential to detect subclinical renal injuries in CNI treated
allograft to guide therapeutic maneuvers of immunosuppressive regimens in kidney
transplantation. Identification of molecular signatures based on analyses of CNI
nephrotoxicity disease pathways and differential gene expression allow the establishment
of a standardized and non-invasive system of specific biomarkers characterizing
pathologies of CNI nephrotoxicity and its potential contribution to the development of
IF/TA. The outcome will offer the potential of stratifying CNI nephrotoxicity and
possibly optimizing the benefit to risk ratio of drug treatment by using biomarkers as
diagnostic tests.
VII. Study Rationale
Adverse drug effects induced by calcineurin inhibitors cause nephrotoxicity,
which leads to allograft dysfunction and possibly to late-term graft loss in kidney
transplant recipients. A differential diagnosis of this toxicity remains a clinical challenge
because of the drug‟s low dose-toxicity correlation and varying individual susceptibility.
We hypothesize that calcineurin inhibitor nephrotoxicity follows specific disease
pathways and has significant molecular signatures that differentiate it from other
diagnoses such as interstitial fibrosis/tubular atrophy and acute cellular and humoral
rejection in kidney transplantation. Moreover, we postulate that CNI-induced toxicity
profiles contribute to the IF/TA signatures. As calcineurin inhibitors are used not only to
prevent acute clinical rejection but also to maintain the functionality of the allograft,
identification of these gene signatures is important in kidney transplant patient
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management as they can be used to monitor calcineurin inhibitor therapeutic effect and
toxicity and also to optimize immunosuppression therapy in kidney transplantation.
VIII. Specific Aims
The following specific aims will be used to test the overall hypothesis:
Aim 1 – To identify specific gene expression changes associated with calcineurin
inhibitor nephrotoxicity when compared with normal function allograft under
calcineurin inhibitor therapy in kidney transplant recipients.
Aim 2 – To validate a set of differentially expressed genes from the microarray
results using real-time PCR.
Aim 3 – To validate differential expression of the candidate signatures, identified
in Aim 2, in an independent set of kidney samples.
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CHAPTER 2: RESEARCH MATERIALS AND METHODS

I. Patient and Sample Selection
This research project involved 27 kidney-transplant-recipients of deceased donor
kidneys. Written informed consent was obtained from all patients. All samples were
collected from biopsies of these patients at 9 month or later post transplantation using an
18-gauge biopsy needle. All the biopsies were histologically evaluated according to the
Banff criteria and categorized into appropriate groups. Calcineurin Inhibitor (CNI) group
included 9 patients with reported biopsy histological changes consistent with CNI
nephrotoxicity described in the revised Banff „07 schema at least 9 months after
transplantation. Interstitial fibrosis/tubular atrophy (IF/TA) group was consisted of 10
patients with reported biopsy histological changes consistent with IF/TA of the Banff
criteria at 9 months or later after transplantation. Normal function allograft (NFA) group
was consisted of 8 patients with 9 months or longer follow up with a continuing
glomerular filtration rate (GFR) of >60ml/min/1.73m2 with no reported incidence of CNI
and/or ACR. The biopsies were instantly submerged in RNAlater (Ambion, Austin, Tx,
USA) and homogenized.
II. RNA Isolation from Kidney Tissues
1. RNA Isolation From Frozen Tissues
TRIZOL reagent was used to extract total RNA from frozen kidney tissues for our
microarray analysis because it demonstrated to perform well with small quantities of
tissues (50-100mg) of human and other species for research purposes according to its
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manufacturer. RNA isolation with TRIZOL reagents also allows maintaining the
integrity of the RNA while disrupting cells and dissolving cell components. RNAs
yielded are free of protein and DNA contamination, which greatly contribute to the
quality of RNA to be used in real-time PCR reactions and further analysis.
The reagent is a mono-phasic solution of phenol and guanidine isothiocyanate.
During sample homogenization or lysis, TRIZOL reagent maintains the integrity of the
RNA, while disrupting cells and dissolving cell components. Addition of chloroform
followed by centrifugation, separates the solution into an aqueous phase and an organic
phase. RNA remains exclusively in the aqueous phase. After transfer of the aqueous
phase, the RNA is recovered by precipitation with isopropyl alcohol. After removal of the
aqueous phase, the DNA and proteins in the sample can be recovered by sequential
precipitation. Precipitation with ethanol yields DNA from the interphase and an
additional precipitation with isopropyl alcohol yields proteins from the organic phase.
2. RNA Isolation from Formalin-Fixed, Paraffin-Embedded Tissues
RNA isolation was performed using the High Pure RNA Paraffin Kit, 2009, Roche
for formalin-fixed, paraffin-embedded (FFPE) samples/tissues in accordance with the
manufacturer‟s protocol. This kit was chosen for the study because it is specifically
designed to extract total nucleic acids (RNA, miRNA, and DNA) from FFPE tissues and
according to its manufacturer, the recovered products are suitable for quantitative realtime RT-PCR (55).
The formalin-fixed and paraffin-embedded kidney sections of 5m thickness were
incubated at in xylene solution overnight to initiate the de-paraffinization step. Once the
paraffin melted and separated from the tissue samples, several washes with ethanol were
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carried out in order to remove the excess xylene from the sample and accelerate drying of
the tissue. Digestion buffer and protease were then added to the solution and allowed to
incubate at 55C overnight to break and free the covalent bonds between the proteins and
the nucleic acids. Then a series of rigorous washing steps was necessary to purify the
nucleic acids. The final products are captured on the provided glass-fiber filter. The
isolated RNA was stored immediately at -80C freezer until needed for later analyzing.
III. Quantity Measurement and Quality Assessment of Isolated RNA
To determine quantity and quality of RNA in each sample, spectrophotometer
readings were analyzed. 1L of RNA isolated from each sample was aliquotted for
spectrophotometer reading using NanoDrop 1000 Spectrophotometer. The absorbance
reading at 260 nm was used to calculate the RNA concentration and the ratio of A260/A280
absorbance readings were used to measure the level of RNA purity from any DNA
contamination. Typically, the ratio of 1.8-2.1 would be the ideal values for these isolated
samples. The ratio of A260/A270 absorbance readings was used to observe for any
contamination with phenol.
RNA purity as measured by spectrophotometer is deemed sufficient, providing
the ratios satisfy the criteria A260nm/A280nm >1.8 and A260nm/A270nm >1.3.
Additionally, the RNA integrity, assessed by capillary electrophoresis using the Agilent
Bioanalyzer (Agilent Technologies), must meet the criteria that the 28S/18S ratio >1.5.
We established a cutoff value of 30% rRNA contribution to the total area under the
electropherogram for RNA samples to be considered as intact or undergraded. Products
of cDNA synthesis and in vitro transcription (IVT) were tested using the Agilent 2100
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Bionalyzer (cDNA synthesis 1.5 kb < cDNA < 5.0 kb; IVT 1.0 kb < cRNA < 4.5 kb).
Assessment of RNA quality was also made using data from the hybridized GeneChips.
IV. Real Time- QPCR
TaqMan Q-PCR (Real Time – Polymerase Chain Reaction) was carried out for
the amplification step of the PCR products from the cDNA, using the TaqMan Universal
Master Mix without AmpErase UNG (uracil-N-glycosylase) (Figure 3). The purpose of
UNG is to prevent PCR carryover products by hydrolyzing any uracil-glycosidic bonds to
block DNA polymerase replication. However, due to the fact that many of our RNA
samples being fragmented and degraded from FFPE processing and being aged, it was
decided to exclude the AmpErase UNG from the Master Mix so we could maximize the
RNA that remained in our samples. 1.0L of the RT products was added to the 19.0L of
the reaction mixtures. The ABI Prism 7700 Sequence Detector was set at conditions of
95C for 10 minutes (denaturation step), 92C for 15 seconds (annealing step), and 60C
for 60 seconds (extension step), which was repeated for 40 cycles. The amplification for
mRNA was performed in duplicates along with the endogenous control GAPDH
(Glyceraldehyde-3-phosphate dehydrogenase). GAPDH was employed as the
housekeeping gene because it is stably expressed under the defined experimental
conditions and sufficiently abundant across different tissues and cell types (including
kidney).
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Figure 2: An Overview of Taqman Protocol (Taqman protocol)
What makes this assay robust from any other PCR is that TaqMan uses a sequence
specific probe that anneals to the complementary sequence of the interested target site.
The probe contains a FAMtm reporter dye at the 5‟ prime end and a nonfluorescent
quencher (NFQ) at the 3‟ prime end, followed by a minor groove binder (MGB), which
prevents probe lengthening. When the probe binds to its complementary sequence in
between the forward and reverse primer sites during PCR, the distance between the
reporter dye and the quencher dye prevents any florescence activity (Figure 4). However,
once the DNA polymerase begins synthesizing the new strand and reaches the annealed
probe, it will cleave the probe, free the reporter dye from the quencher dye, and the
separation will cause the reporter dye to fluoresce. The ABI Prism 7700 Sequence
Detector will capture the fluorescence signal, indicating that the target of interest has
been detected and amplified.
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Figure 3: Basics Of 5‟Nuclease Assay (Taqman Protocol)
The results portrayed amplification curves and Critical Threshold (Ct) values for
each reaction. The duplicate Ct values for each sample were averaged. No template
controls (NTC) were also included in each run to ensure no false positive had occurred.
The Ct value of the mRNA was subtracted from the Ct value of the GAPDH to give the
first delta Ct value. Delta-delta calculations were carried out to evaluate the fold change
between the control group and the group of interest.
V. Description Of Microarray Assay
Study of gene expression in our study was done using Affymetrix microarray
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technology. According to the manufacturer, up to 1.3 million different oligonucleotide
probes are synthesized on each Affymetrix array. Each oligonucleotide is located in a
specific area on the array called a probe cell. Each probe cell contains hundreds of
thousands to millions of copies of a given oligonucleotide. Probe arrays are manufactured
in a series of cycles. Initially, a glass substrate is coated with linkers containing
photolabile protecting groups. Then, a mask is applied that exposes selected portions of
the probe array to ultraviolet light.
Illumination removes the photolabile protecting groups enabling selective
nucleoside phosphoramidite addition only at the previously exposed sites. Next, a
different mask is applied and the cycle of illumination and chemical coupling is
performed again. By repeating this cycle, a specific set of oligonucleotide probes is
synthesized with each probe type in a known location. The completed probe arrays are
packaged into cartridges. Biotin labeled RNA fragments are hybridized into probe arrays
and stained with streptavidin phycoerythrin conjugate and scanned by the
GeneArray® Scanner or the GeneChip® Scanner 3000. The amount of light emitted at 570
nm is proportional to the bound target at each location on the probe array
With minor modifications, the sample preparation protocol followed the Affymetrix
GeneChip Expression Analysis manual (Santa Clara, CA, USA). Briefly, total RNA was
reverse-transcribed using T7-polydT primer, and converted into double-stranded cDNA
using Superscript Choice System (One-Cycle Target Labeling and Control Reagents,
Affymetrix), with templates used for an in vitro transcription reaction at 37°C for 8 h to
yield biotin-labeled antisense cRNA. The labeled cRNA was chemically fragmented and
made into a hybridization cocktail according to the Affymetrix GeneChip protocol, and
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was then hybridized to U133A 2.0 GeneChip probe arrays (Affymetrix). The array image
was generated by the high-resolution GeneChip Scanner 3000 (Affymetrix). All CEL
files all chips passed quality control, the data were processed using Affymetrix GeneChip
Operating software.
VI. Microarray Data Analysis
Probe set expression summaries for the Affymetrix GeneChip data were calculated
using the robust multiarray average method. Statistical methods including linear
regression and empirical Bayes were used to discriminate the gene signals under different
conditions. P-value was the main criterion to select the differentially expressed genes. A
genes with p-value less than 0.001 were considered as potentially differentially expressed
under the pathological conditions (either CNI or IF/TA). Normal function allograft was
used as the control group. The results were presented in Venn diagram.
VII. Gene Annotation
Gene ontology and gene interaction analyses were executed using Ingenuity
Pathways Analysis tools 9.0 (http:// www.ingenuity.com). The gene lists containing
Entrez GeneIDs as clone identifiers, as well as fold-change values from corresponding
supervised analyses, were mapped to their corresponding gene object in the Ingenuity
Pathways Knowledge Base (IPKB). These so-called focus genes were then used in the
network generation algorithm, based on the curated list of molecular interactions in
IPKB. Significance for the enrichment of the genes in a network with particular biologic
functions was determined by the right-tailed Fisher exact test, using a list of all the genes
on the array as a reference set. In addition, an HTML page listing all significant probe
sets with their associated Entrez ID, gene symbol, Unigene ID, chromosomal location,
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and gene name with appropriate hyper links were produced to expedite follow-up.
VIII. Validation of Microarray Data
1. Selection of Kidney Biopsies
To validate our microarray results, we carried out a quantitative real time PCR for
genes selected as the potential signatures characterizing calcineurin inhibitor
nephrotoxicity and its speculated progression to the development of IF/TA. RNA samples
used to validate were isolated from kidney biopsies that were used in microarray analysis
CNI group included 11 samples with reported histological changes consistent with
CNI nephrotoxicity at least 9 months after transplantation. Interstitial fibrosis/tubular
atrophy (IF/TA) group was consisted of 7 samples with reported biopsy histological
changes consistent with IF/TA of the Banff criteria at 9 months or later after
transplantation. Normal allograft (NA) group was consisted of 9 samples with 9 months
or longer follow up with a continuing estimated glomerular filtration rate (GFR) of
>60ml/min/1.73m2 with no reported incidence of CNI and/or ACR.
2. Q-PCR Validation of Microarray Analysis
Each assay consisted of two unlabeled PCR primers and a FAM dye-labeled
TaqMan MGB probe. The endogenous control, GAPDH, was detected with a VIC dyelabeled TaqMan MGB probe (human GAPDH endogenous control, VIC/ TAMRA Probe;
Primer Limited, Applied Biosystems). Total RNA from each sample was subjected to
reverse transcription using TaqMan Reverse Transcription Reagents (Applied
Biosystems) according to the manufacturer‟s protocol. Real-time PCR reactions were
carried out in a 20-μL reaction mixture using an ABI Prism 7700 sequence detection
system (Applied Biosystems).
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All amplifications were carried out in duplicate, and threshold cycle scores were
averaged for calculations of relative expression values. The Ct scores for genes of interest
were normalized against Ct scores for the corresponding GAPDH control. Relative
expression was determined by the following calculation where the amount of target is
normalized to an endogenous reference (GAPDH RNA) and relative to an arbitrary
calibrator (the reference class of patients used in the comparison) (18): relative
expression = 2-ΔΔCt, where ΔΔCt = ΔCt experimental group – ΔCt calibrator group.
3. Statistical Analysis
Student t-tests were used to compare the expression of RGS1, CXCR4, and TGIF1 in
samples (CNI, IF/TA, and NA groups) using their Ct values (Ct =Ct (target gene) – Ct
(endogenous control)).

Pearson‟s Correlation Analysis (using delta Ct values) was used to

observe the correlation between (1) the expression of target genes (RGS1, CXCR4, and
TGIF1) and the pathology of CNI nephrotoxicity and (2) the expression of target genes
(RGS1, CXCR4, and TGIF1) and the pathology of IF/TA. Pearson‟s Correlation
Coefficient of 1 indicates strong correlation. For all of the above tests, p<0.05 was
considered significant.
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CHAPTER 3: RESULTS

I. Patient Demographics and Clinical Values
Molecular biological analysis was done based on biopsies of 27 kidneytransplant-recipients of deceased donors (23 patients are treated with tacrolimus and 4
patients are treated with cyclosporine). Table 2 bellow summarizes patient demographic
information of this study and clinical data.
Table 2: Patient Sample Demographics And Available Clinical Values
NFA: Normal Function Allograft, CNI: Calcineurin Inhibitor; IF/TA: Interstitial Fibrosis/Tubular Atrophy; SD:
Standard Deviation; Bx: Biopsy, eGFR: estimated Glomerular Filtration Rate.

Recipient age (years)
Recipient race
White
African American
Others
Donor age (years)
Donor race
White
African American
Others
Creatinine (mg/dL)
Day 1
Day 2
1 week
1 month
3 months
9 months
12 months
At time of Bx
eGFR at 12 months

NFA (N=8)
Average SD
49.0 + 14.7

CNI (N=9)
Average SD
50.9 + 10.4

IF/TA (N=10)
Average SD
46.4 + 9.6

1
6
1

2
7
0

1
9
0

36.0 + 14.4

54.8 + 4.4

37.7 + 11.3

4
4
0

5
3
1

6
4
0

6.8 + 1.8
5.2 + 1.5
1.7 + 1.1
1.2 + 0.3
1.2 + 0.5
1.0 + 1.6
1.3 + 0.6
1.24 + 0.6

7.3 + 2.3
6.5 + 1.9
4.5 + 1.7
2.6 + 2.2
2.3 + 1.0
3.0 + 1.4
2.3 + 0.8
3.17 + 2.0

8.8 + 2.6
8.1 + 2.6
6.0 + 1.8
1.7 + 0.8
1.5 + 0.3
2.0 + 0.8
1.9 + 1.0
6.44 + 1.6

> 60

33 + 12.9

<25
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As described in chapter 2, Research Materials and Method, the kidney biopsies
used for our study were categorized into three groups, including normal function allograft
(NFA), calcineurin inhibitor nephrotoxicity (CNI), and interstitial fibrosis/tubular atrophy
(IF/TA) according to the Banff ‟07 for Renal Allograft Pathology (Table 3).
Table 3: Histological Evaluation of Kidney Biopsies Using Banff ‟07 Update.
Patients
Banff ’07 Classification for Diagnosis
Renal Allograft Pathology
Banff 5I
Normal Function Allograft
1
Banff 5I
Normal Function Allograft
2
Banff 5I
Normal Function Allograft
3
Banff 5I
Normal Function Allograft
4
Banff 5I
Normal Function Allograft
5
Banff 5I
Normal Function Allograft
6
Banff 5I
Normal Function Allograft
7
Banff 5I
Normal Function Allograft
8
Banff 6
Calcineurin-Inhibitor Nephrotoxicity
9
Banff 6
Calcineurin-Inhibitor Nephrotoxicity
10
Banff 6
Calcineurin-Inhibitor Nephrotoxicity
11
Banff 6
Calcineurin-Inhibitor Nephrotoxicity
12
Banff 6
Calcineurin-Inhibitor Nephrotoxicity
13
Banff 6
Calcineurin-Inhibitor Nephrotoxicity
14
Banff
6
Calcineurin-Inhibitor Nephrotoxicity
15
Banff 6
Calcineurin-Inhibitor Nephrotoxicity
16
Banff 6
Calcineurin-Inhibitor Nephrotoxicity
17
Banff 5II
Interstitial Fibrosis/Tubular Atrophy
18
Banff 5II
Interstitial Fibrosis/Tubular Atrophy
19
Banff 5III
Interstitial Fibrosis/Tubular Atrophy
20
Banff 5III
Interstitial Fibrosis/Tubular Atrophy
21
Banff
5II
Interstitial Fibrosis/Tubular Atrophy
22
Banff 5II
Interstitial Fibrosis/Tubular Atrophy
23
Banff 5III
Interstitial Fibrosis/Tubular Atrophy
24
Banff 5III
Interstitial Fibrosis/Tubular Atrophy
25
Banff 5II
Interstitial Fibrosis/Tubular Atrophy
26
Banff 5II
Interstitial Fibrosis/Tubular Atrophy
27
II. Microarray Results
Statistical analysis of microarray data from the biopsies collected at least 9-month
post-transplantation (based on p-value of less than 0.001) showed that 498 genes were

33

identified as unique differentially expressed genes to the conditions of CNI vs. NFA and
3371 were unique for IF/TA vs. NFA (Figure 4). The overlapped genes, 449 genes, which
showed the same direction of gene expression (either up-regulation or down-regulation),
can possibly contribute to the progression of CNI to IF/TA as seen in figure 9.

Figure 4: Venn Diagram (identified segregation of deregulated
genes in CNI vs. NFA and IFTA vs. NFA (Using TOPPGENE software )

III. Biological Networks and Pathway Analysis in CNI Population
Core analysis was performed to interpret the data set in the context of biological
processes, pathways and molecular networks.
1. Top Ten Networks of Interaction
Probe sets differentially expressed in CNI samples (N = 498) were overlaid onto a
global molecular network developed from information contained in the IPKB. This is a
network of gene interactions, which are algorithmically generated and then ranked based
on a number of score corresponding to the likelihood of a set of genes being found in the
networks due to chance. To illustrate, a score of 3 indicates that there is a 1/1000 chance
that focus genes are in a network due to the chance. Therefore, a score of 3 or higher has
a 99.9% confidence of not being generated by chance alone. Top ten score-based
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biological networks associated with calcineurin inhibitor nephrotoxicity were reported in
the Table 4 below.
Table 4: Biological Networks Ranked By Score in CNI Tissues
Focus
I
Scor Molecule
D Molecules in Network
e
s
AFF2, AKAP2/PALM2-AKAP2,
BRD4, DLX4, FH, GRB2, HIBCH,
Histone h4, HNRNPH1, HNRNPR,
Importin alpha, Importin beta, KCNB2,
KPNA3, NUTF2, P-TEFb, PDIA4,
PHACTR2, PXDN, RBM25, RPL12,
SAE1, SIRT3, SIRT4, SMARCD3,
SPEN, SRP19, SYNCRIP, SYT2,
TBL1X, TNPO1, UBA52, WDR44,
1 XPO7, ZBTB7A
42
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ALB, ARF4, CAPG, CD3, CDC42,
CLCN4, DEFA5, DMWD, Gsk3,
HAND1, JUN, KIAA0930, KLC1,
LSR, MAPK8, MBP, MZF1,
NDUFA5, NRP1, P38 MAPK,
PLXNA1, PRB3, PRKCA, Proinflammatory Cytokine, SETX,
SH3BP5, SLC1A1, SPAG9, SUCLG2,
SYNE1, TCF20, TCR, TRD@, Vegf,
2 YWHAB
36
29
AAK1, ABCC1, Adaptor protein 2,
ALDH6A1, ALDOA, AP-3, Ap2 alpha,
AP2B1, AP3D1, ATPase, BAZ1A,
C10orf10, CD1B, Clathrin, DLGAP2,
EHMT2, GABAR-A, GABRA1,
GABRA5, GABRR2, GRIN2A,
H3F3A/H3F3B, IL1RAPL1, NECAP2,
Pias, PLSCR1, QKI, RALBP1,
RBFOX2, RERE, SHC1, SMARCA5,
3 SMCP, SRRM2, Top2
33
27
APBA1, APBB2, APH1A, APP,
ATP5J2, BAX, BCL6, CAMKK2,
CLOCK, COX10, Cytochrome c
oxidase, DAD1, Dynein, FAM173A,
FEZ2, Gm-csf, H2AFX, HADH,
HAP1, IL12 (family), LIN7B, MCL1,
Notch, PCM1, PSEN2, PYCARD,
4 RER1, RTN2, Secretase gamma,
32
28
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Top Functions

Post-Translational
Modification,
Genetic Disorder,
Metabolic Disease

Cellular
Development,
Nervous System
Development and
Function, Cellular
Assembly and
Organization

Molecular
Transport, Genetic
Disorder,
Neurological
Disease

Cell Death, Renal
Necrosis/Cell
Death, Cellular
Assembly and
Organization

5

6

7

8

9

SGPL1, SMC3, SRI, TIP60, UBXN4,
ZNF24
26s Proteasome, ALDH1A3, ANP32B,
ATG12, ATRX, AZGP1, BRD2,
CCND1, CNOT1, CSN2, Ctbp,
GATAD2A, Hat, HIST1H4C (includes
others), HISTONE, Histone h3,
HNRNPA0, JUNB, KCNA5, KHK,
MAFF, MBD1, N4BP1, PDE4DIP,
POP7, PRNP, Ptk, RPL36, Rsk,
SERBP1, SET, STAT, TGIF1, TP63,
USP22
ADAM17, AFF1, ARHGEF40, C3,
CCBP2, CDKN1A, CHEMOKINE,
Ck2, CTSZ, DNA-directed RNA
polymerase, DSE, DUSP1, Dynamin,
GPSM2, GTF2H4, GYPA, Holo RNA
polymerase II, HRAS, IgG,
Immunoglobulin, KLF7, MED28,
MED13L, Mediator, MEF2C, NKTR,
POLR2D, POLR2L, POLR3C, RNA
polymerase II, RNF7, STC2, TXLNA,
VGLL4, ZMPSTE24
APPBP2, C5orf13, CUL2, CYR61,
DBI, DDX24, EIF5B, FXR2,
HEATR6, HIF1A, Ikb, LYN,
MFHAS1, MTDH, MYC, NFkB
(complex), NFkB (family), NR3C1,
Orm, OTUB1, PLAGL1, PRRC2C,
RALYL, RELT, SERINC3, TFAM,
Tgf beta, TPP2, TSPO, UBE2I,
UBE2K, Ubiquitin, VDAC3, VIM,
VOPP1
ADRA1A, AGTR2, Beta Arrestin,
CYSLTR2, DRD5, F2RL1, FZD2,
GAB1, GABBR2, GLP1R, GNRHR,
Gpcr, GPR12, GPR89A/GPR89B, Gscoupled receptor, Gαq, HRH4, HTR6,
HTR1F, HTR3A, HTR3B, MAS1,
Metalloprotease, P2RY11 (includes
others), Pik3r, RGS1, RRH, Serotonin
Receptor, Shc, SRC, TAAR3, TACR2,
Trk Receptor, VIPR2, VN1R1
3‟,5‟-cyclic-nucleotide
phosphodiesterase, AKAP6, Alpha
tubulin, ANXA2, APC, APEX1,
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32

30

30

27

Cell Cycle, DNA
Replication,
Recombination,
and Repair, Gene
Expression

26

Organismal Injury
and
Abnormalities,
Cell Cycle,
Cellular
Development

28

Cell Morphology,
Hair and Skin
Development and
Function, Cell
Cycle

30

25

29

26

Hematological
Disease,
Immunological
Disease,
Inflammatory
Disease
Protein Synthesis,
Cell Morphology,
Gene Expression

10

CLIC4, CYLD, EIF3A, EIF4A1, Eif4g,
EIF4G3, Hdac, INTS6, MYCN, NRL,
PABPC4, Pde, PDE10A, PDE4A,
PDE6A, Pka, Pka catalytic subunit,
PKP1, RBBP5, Rnr, RPL28, RPL35,
RPLP0, S100A10, STAU1, STMN1,
TUBA1A, TUBA1B, VARS
ACTN1, alcohol group acceptor
phosphotransferase, ATP2A2, Calpain,
CBFB, CCND2, CEP170, COIL,
CSDA, CSNK1A1, Cyclin A, Cyclin
D, DST, DYRK1A, E2f, EPM2A,
FJX1, FSH, GSK3B, hCG, HIF3A,
HIST1H2AB/HIST1H2AE, IGSF1,
INHBB, INHBC, inhibin, Lh,
NOTCH2, PAK2, PGK1, RAB14,
RAB31, Rb, SMYD2, UPP1

29

25

Gene Expression,
Organ
Development,
Organ
Morphology

2. Network Exploration
According to the top ten biological networks significant in CNI population (N =
498) listed above, network 4 (Figure 5) includes deregulated genes that are involved in
cell death, renal necrosis/cell death, cellular assembly and organization. The interactions
of molecules in this network are further explored using IPA tool (www.ingenuity.com)
and it shows that molecules of multiple mediators including cytochrome c are downregulated, while a number of transcription factors are up-regulated.
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QuickTime™ and a
decompressor
are needed to see this picture.

Figure 5: Interaction Network 4 in CNI vs. NFA.
The meaning of the node shapes and interaction edges is indicated on legend list on the right.

Another network that is significant to the toxicology profile of calcineurin
inhibitors is network 8 (Figure 6), with molecules significant in hematological disease,
immunological disease, and inflammatory disease. It shows a general down regulation
various the G-protein coupled proteins, which leads to a noticeable up regulation of
RGS1, regulator of G-protein signaling 1, a molecule that involved in immune response
and negative regulation of signal transduction.
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QuickTime™ and a
decompressor
are needed to see this picture.

Figure 6: Interaction Network 8 in CNI vs. NFA.
The meaning of the node shapes and interaction edges is also indicated on the right.

3. Canonical Pathway Analysis
Canonical pathway analysis (Figure 7) shows that top pathways that are affected are
involved in oxidative stress response and also various cell death-signaling pathways (143-3 mediated signaling pathway, p53 signaling pathway, and TGF- signaling pathway
(Figure 8) in additional to prolactin signaling, rac signaling, cancer, and some others.
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Figure 7: Top Canonical Pathways in CNI vs. NFA. Each bar represents the percentage of upregulated (red) or down-regulated (green) or unaffected/undetected (white) genes within the identified
pathway. The line represents –log(P value).
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Figure 8: TGF- Signaling Pathway. Up-regulated genes are shown in red while down-regulated
genes are shown in green. Unaffected/undetected genes within the identified pathway are in white.

IV. Biological Function and Toxicology Profile of CNI vs. NA and IF/TA vs. NA
differentially expressed genes
Core analysis was also performed to interpret the data set in the context of
biological function and toxicology profiles between CNI group and IF/TA groups
1. Pair-wise Comparison Analysis Between CNI and ITA
In the overlapped genes between CNI and IF/TA (N= 449) as expected, scar
tissues and irreversible damages characterized ITA indicating the increasing effect of
these conditions in cell death. However, oxidative stress response played a bigger role in
calcineurin inhibitor nephrotoxicity than in IF/TA. Some important pathways that
involved in cellular response to injury and inflammation such as p53 and TGF-
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signaling pathways were more affected in calcineurin inhibitor nephrotoxicity when
compared to IF/TA. Yet renal necrosis/cell death is seen much higher allograft diagnosed
with IF/TA than with calcineurin inhibitor nephrotoxicity. Figure 9 summarizes the
findings above.

Figure 9: Comparison in Biological Function of CNI vs. IF/TA
2. Functional analysis of the differential gene expression between groups
In agreement to the above findings, pathology of IFTA underlines a higher degree
of renal necrosis and cell death as compared to that in calcineurin inhibitor
nephrotoxicity. However, other injuries to specific compartments of kidney show the
contrary. Calcineurin inhibitor nephrotoxicity causes more kidney failure, renal nephritis,
glomerular injury, and also nephrosis. Figure 10 summarizes findings above.
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Figure 10: Comparison in Toxicology Function of CNI vs. IF/TA
V. Differential Gene Expression Profiling
1. Criteria for Selecting Genes for Validation
A list of potential gene signatures was selected from the genes annotated for CNI
vs. NA (N= 498). This list was filtered based on biological significance relevant to
pathology of CNI nephrotoxicity with support from literature review and IPA reports. To
determine whether the selected genes were unique to the conditions of CNI
nephrotoxicity or possibly candidates of CNI contribution to IF/TA, the criteria listed in
table 4 of each molecule were thoroughly considered.
Table 5: Criteria For Selecting Genes For Validation
Criteria For Selecting Genes For Validation:
1. Significance of probe set‟s p-value < 0.001
2. Fold changes based on mean expression compared to
Normal Allograft 2.0 or -2.0
3. Biological processes/Molecular functions/Canonical
pathways relevant to CNI nephrotoxiticy
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3. Candidate Differentially Expressed Genes
Among several characteristic genes showed differentially expression between CNI
nephrotoxicity and normal allograft under CNI therapy (N = 498), 9 gene candidates were
selected (Table 6). In addition to the above criteria, these genes don‟t have significant
fold changes in IF/TA (due to either not detected or fold change out of the range of
interest). These genes were also regulated differently via comparison of fold change of
the same genes in IF/TA vs. NA in the opposite direction (i.e. gene was up regulated in
CNI but down regulated in IF/TA).
Table 6: Candidate Genes With Significant Expression in CNI Population.
DIFFERENTIALLY EXPRESSED GENES IN CNI vs. NFA
Affy ID
Gene Symbol
p-Value
Fold change based on
mean expression
216834_at

RGS1

9.87E-04

5.305

203313_s_at

TGIF1

1.22E-04

2.132

200644_at

MARCKSL1

5.36E-04

2.146

211348_s_at

CDC14B

2.27E-05

2.087

202376_at

SERPINA3

7.78E-04

3.804

202598_at

S100A13

4.74E-04

2.406

208993_s_at

PPIG

1.78E-07

3.099

204863_s_at

IL6ST

2.81E-04

2.689

210305_at

PDEDIP

2.25E-04

3.004

Furthermore, out of the differentially expressed genes identified that showed same
direction of regulation in both CNI nephrotoxicity and IF/TA diagnosed allografts (N =
449 overlapped genes), 10 gene candidates were selected (Table 7). Besides the criteria
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above, these genes also characterize both CNI and IFTA with fold changes in the same
direction (i.e. a gene that is up regulated or down regulated in both conditions). Also
these fold changes must show significant difference when compared to one another (i.e.
the difference in fold changes must be greater than 2 times). These candidate genes can
serve as molecular signatures for further studied in understanding of the contribution of
CNI nephrotoxicity to the development of IF/TA.
Table 7: Candidate Genes With Significant Expression In CNI And IF/TA
(Normal Function Allograft was used as the control group. Several fold change were reported in
accordance to more than one probe set was detected for the specific genes.)

DIFFERENTIALLY EXPRESSED GENES IN CNI vs. NFA AND IF/TA vs. NFA
Affy ID
Gene
p-Value
p-Value
Fold change based on
Symbol
CNI vs. NFA IF/TA vs. NFA
mean expression
CNI vs.
IFTA vs.
NFA
NFA
209201_x_at
CXCR4
2.26E-04
4.17E-13
3.328
21.573
209880_s_at

PLG

2.10E-04

6.27E-11

-5.335

-39.038

209309_at

AZGP1

1.58E-12

6.67E-08

-3.295

201041_s_at

DUSP1

6.60E-11

6.94E-06

3.777

-53.489
-8.568
11.464

206332_s_at

IFI16

2.21E-10

2.97E-12

2.716

212587_s_at

PTPRC

2.46E-12

6.75E-07

2.632

221666_s_at

PYCARD

2.16E-08

2.16E-08

2.505

7.260
4.255
3.937
14.551
5.807
6.177
-1.453
5.973

219803_at

ANGPTL3

4.33E-14

4.33E-14

-2.805

-35.496

204704_s_at

ALDOB

1.22E-11

1.22E-11

-2.109

221731_x_at

VCAN

5.86E-13

7.84E-10

4.201

-234.364
-147.464
-142.546
-3.026
14.006
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4. Selected Genes for Validation
With the listed criteria, three genes were chosen for the study (Table 8). These
genes were further validated using real-time PCR on an independent set of kidney tissues.
Table 8: Characteristic Genes For CNI Nephrotoxicity

Affy ID

Gene
Symbol

1

216834_at

RGS1

2

1566901_at

TGIF1

3

209201_x_at

CXCR4

Biological Significance To
CNI Nephrotoxicty

Reference
s

Involved in immune response and negative
regulation of signal transduction
Over-expressed in regulatory T cells in
immunology tolerance
54-57
Is an active transcriptional co-repressor of
SMAD2 in TGF- signaling pathway –
might involved in the mechanisms of renal
interstitial fibrosis
58-61
Interacts with cyclophilin A involved in
physiological and pathological conditions
such as human immunodeficiency virus
infection and cancer metastasis
Involved in p38-dependent T cell apoptosis 62&63

VI. Q-PCR Confirmation of Microarray Data
For the selected genes we observed good correlation between QPCR and
microarray results using 6 CNI samples and 6 NA samples of RNAs that were also used
in the microarray analysis. The results of two-sample t-tests for this set was calculated
and reported in table 9.
Table 9: T-test Of Genes Used In Confirmation
T-tests (* denotes a significant t-test result)
RGS1

CXCR4

TGIF1

CNI vs. NA

0.038*

0.246

0.245

IF/TA vs. NA

0.006*

0.036*

0.328

CNI vs. IF/TA

0.412

0.147

0.172
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The 2-Ct calculations were carried out to demonstrate the relative fold changes
of RGS1, CXCR4 and TGIF1 in confirmation of the microarray data. The results of these
calculations were reported in table 10 along with standard deviation for each fold change
Table 10: Relative Fold Change of Gene Expression
(With NFA group as reference)
Relative Fold Change of Target Gene Expression

Fold
Change

RGS1

CXCR4

TGIF1

CNI

38.88 + 0.99

3.30 + 1.58

0.32 + 2.73

IFTA

76.07 + 2.66

9.17 + 1.45

0.89 + 3.70

To observe the correlation between the level of expression of RGS1, CXCR4, and
TGIF1 and the pathology of CNI nephrotoxicity as well as the pathology of IF/TA, a
Pearson‟s Correlation Analysis was calculated. The results were summarized in table 11
below.
Table 11: Pearson‟s Correlation Coefficient Values
Pearson’s Correlation (*denotes a significant correlation)
RGS1

CXCR4

TGIF1

CNI

0.37

-0.65*

0.61*

IF/TA

-0.75*

0.62*

0.21

VII. Q-PCR Validation
To validate microarray data of RGS1, CXCR4, and TGIF1, real-time PCR was
performed in an independent set of sample tissues (N= 18, CNI = 11 and NA =7). The
results of two-sample t-tests, which revealed the significant differential expression of the
genes of interest between CNI and IF/TA tissues and normal allograft, and between CNI
and IF/TA groups, were calculated and reported in table 12 below.
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Table 12: T-test of Genes In Validation
T-tests (* denotes a significant t-test result)
RGS1

CXCR4

TGIF1

CNI vs. NA

0.015*

0.115

0.755

IF/TA vs. NA

0.001*

0.004*

0.849

CNI vs. IF/TA

0.139

0.062

0.836

The 2-Ct calculations were carried out to demonstrate the relative fold changes
of RGS1, CXCR4 and TGIF1 in study samples of CNI and IFTA (Table 13).
Table 13: Relative Fold Change of Validated Genes
(With NFA group as reference)
Relative Fold Change of Target Gene Expression

Fold
Change

RGS1

CXCR4

TGIF1

CNI

15.48 + 0.81

3.09 + 1.09

1.27 + 1.24

IFTA

42.05 + 2.73

7.96 + 2.67

1.12+ 2.78

Figure 11 summarizes the fold changes based on calculations above of RGS1,
CXCR4, and TGIF1 in kidney samples of the study. It showed that expression of genes of
the study had a positive direction in both CNI and IF/TA tissues.

Figure 11: Fold Change In Gene Expression of CXCR4, RGS1 and TGIF1
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1. RGS1 expression
The differential expression of mRNA RGS1 in CNI tissues was first evaluated
through analysis of comparison the gene expression in the CNI tissues versus normal
allograft, IF/TA tissues versus normal allograft, and between pathological groups (CNI
versus IF/TA). Three two-sample t-tests were performed. The t-test values of p = 0.015
and p = 0.001 showed significant differential expression between pathological groups
when compared with normal allograft, CNI vs. NA and IF/TA vs. NA respectively. Even
though the t-test (p = 0.139), performed on the mean Ct values between CNI and IF/TA
samples, showed no statistical significant differences in the level of RGS1 expression, we
noticed a positive and up-regulated pattern of this gene expression in IF/TA tissues when
compared to that in CNI tissues. According to the calculated fold change of RGS1, this
particular gene expression in IF/TA kidney tissues was about 3 times higher of that in
CNI kidney samples. Pearson‟s correlation showed a negative correlation of RGS1 in
IF/TA but not in CNI (-0.75 and 0.37 respectively) or a negative relationship between the
expression of this gene seen in microarray data and that in q-PCR validation (Aim 2).
2. TGIF1 Expression
Since TGIF1 was also collected as one of the three candidate genes for this
present study on calcineurin inhibitor nephrotoxicity based on its significant in statistical
microarray value and biological relevance, we also performed real-time PCR reactions
for this gene to observe and validate the correlation of the gene expression pattern with
the drug-induced toxicities. Two-sample t-test based on mean Ct values between groups
of the study did not show any significance in the level of TGIF1 expression in either
tissues with pathologies (CNI or IF/TA) or tissues of normal allograft. Computation of
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the gene fold changes in CNI group and IF/TA group showing a large standard deviation
also confirmed no significant expression level between analysis groups. Despite this,
expression level of TGIF1 showed a positive correlation (0.61) between microarray data
analysis and q-PCR validation result in CNI group, according to its Pearson‟s correlation
coefficient.
3. CXCR4 Expression
In a similar with the above assessment of the qPCR results of RGS1 and TGIF1,
mRNA expression, gene expression patterns of CXCR4 were also mathematically
evaluated in three pairs of comparison between groups of sample tissues. Student‟s t-test
with p values of 0.115 and 0.062 suggested no significant differential expression of this
gene in CNI tissues when compared with normal allograft and also between CNI tissues
and IF/TA tissues. However, student‟s t-test revealed p = 0.004 indicating differential
expression of the mean Ct values between IF/TA group and normal allograft being
statistically significant. Relative fold change of CXCR4 in IF/TA group was calculated to
be 7.96 and 3.09 in CNI group. According to Pearson‟s Correlation Analysis, CXCR4
showed significant correlation in both CNI and IF/TA with r=-0.65 and 0.62 respectively.
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CHAPTER 4: DISCUSSION

Cyclosporine and tacrolimus are potent immunosuppressive therapeutic agents,
which selectively target calcineurin and NFAT signaling pathway to suppress Tlymphocyte activation and proliferation. Their pharmaceutical benefit in kidney
transplantation is, however, limited because of undesirable adverse effects. Direct
toxicities induced by calcineurin inhibitors on kidney allograft, in fact, cause
nephrotoxicity, which is a complex consequence of disturbance in hemodynamic balance,
inflammatory response, and structural damages to the nephrons. Retrospective studies on
calcineurin inhibitors report that, at five years after transplantation, developing
nephrotoxicity is almost universal in kidney transplant patients (26).
Reduction in CNI dose, withdrawal of CNI, or CNI-free therapies show
improvement in signs and symptoms of nephrotoxicity. However, due to high risk of
acute rejection and lack of long-term validation, calcineurin inhibitors are still widely
administered as the standard maintenance immunosuppressive therapy in solid-organ
transplantation (34). Management and treatment of toxicities induced by CsA and FK506
continue to be a major clinical challenge due to variable individual susceptibilities and
difficulty in establishing a differential diagnosis.
We were aware of the impact of gene polymorphism in pharmacokinetics and
pharmacogenetics on individual response to CNI-induced toxicities on kidney allograft.
Previous research groups found many genes involved in the renin-angiotensin system,
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which contributes largely to the disturbance in hemodynamic balance of the transplanted
kidney, and several others involved in the CNI pharmacokinetics greatly affecting the
drug efficacy and extend of toxicity in individual body system (26,34,35). Clinical
indication of these genes has been made apparent because of their immediate relevancy to
individual susceptibility to CNI nephrotoxicity. Clinical application of these genes, not in
absolute term but in the relation to the etiology and pathological mechanisms of CNI
nephrotoxicity in kidney transplant patients, is significant, however, limited due to the
challenging clinical presentation of toxicities induced by CNI.
In clinical practice, conventional parameters such as drug plasma level, creatinine
level, and estimated GFR fail to predict either rejection or toxicity because of the drug‟s
narrow therapeutic window and low correction between dose-toxicity (26,35). The
current standard diagnosis of CNI nephrotoxicity is largely relied on histological
assessment using the revised Banff ‟07 criteria (7). However, CNI nephrotoxicity pathomorphological representations have poor reproducibility, which could be subjective and
interfered by tissue heterogeneity as well as pathologist‟s expert prejudice (20,21).
Since lacking a defined differential diagnosis of CNI nephrotoxicity undermines
the effectiveness of the current therapeutic monitoring effort and strategies for patient
treatment, our study was aimed to establish molecular profiles unique to CNI
nephrotoxicity. Microarray data collected from CNI nephrotoxicity kidney tissues of 27
kidney transplant recipients was analyzed in the context of biological functions and gene
interactions, using normal allograft as the control group.
Top biological networks based on score in CNI population was associated with a
wide range of biological functions such as metabolic disease, cellular development, renal
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necrosis, apoptosis cell-death, immunological disease, inflammatory disease, and many
others. It underlined the multifaceted nature of calcineurin inhibitor nephrotoxicity and
the fact that calcineurin has various physiological substrates, beside NFAT, in immune
and non-immune cells.
Survey of genes in cell death, renal necrosis/cell death, and cellular assembly and
organization (network 4) revealed an up-regulation of multiple transcription regulators
such as BCL6, ZNF24, PYCARD in contrary to a down-regulation of transcription
regulator CLOCK. Over-expression of BAX, BCL2 associated X protein, observed in
network 4 demonstrated the involvement of mitochondrial destruction in apoptosis cell
death pathway of CNI nephrotoxicity as suspected in previous research studies. The
proposed mechanism concerned the binding of cyclosporine A to cyclophilin D, a unique
mitochondrial isoform of cyclophilin in mammals, which led to detachment of
cyclophilin-D from mitochondrial membrane causing permeability of the transition pore
(42). BAX is known for its molecular function in release of cytochrome c from
mitochondria and activation of caspase activity by cytochrome c. This finding carried on
the impact of non-immunological interactions of CNI in cells.
Gene expression patterns of molecules in interaction network of hematological
disease, immunological disease, and inflammatory disease (network 8) depicted negative
regulation of many G-coupled proteins but a noticeable increase in expression of
regulator of G-protein signaling1 (RGS1, p = 9.87E-04). The deregulation pattern of
RGS1, among the three final gene candidates of this study, was investigated in CNI group
for its potential value as a biomarker. RGS1 was found to play an important role in
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multiple cellular processes including negative regulation of signal transduction and
immune response (54).
In vitro and in vivo studies of human RGS1 mRNA in isolated T lymphocytes
indicated that an over-expression of this gene, especially in subset of host T cells with
regulatory function or Treg, was essential in immunology tolerance (54,56). As Treg is
known to play an important role in suppressing the activation of immune response and
has been found to be inhibited by CNIs, with the possible mechanism via suppression of
IL2 production and signal transduction. (54-57). Analyses on proliferation and activation
of Treg in kidney allograft treated with immunosuppressive agents, furthermore, showed
that population of Treg in allograft treated with CsA-based in compared with sirolimusbased regimen is significantly lower (55,57).
Quantitative validation of RGS1 with real-time PCR, furthermore, upheld the
synergistic relationship of the up-regulation of this gene and the disease course of CNI
nephrotoxicity. However, contrary to our previous finding that RGS1 was only detected
in CNI group with a significant p value and fold change, a differential expression of
RGS1 level was also detected in IF/TA group when compared to normal allograft. mRNA
RGS1 was expressed at a much higher fold change in IF/TA group and in the same
positive direction as observed in CNI group. This finding suggests the possible
involvement of RGS1 in the pathway that CNI nephtoroxicity progresses to the
development of IF/TA.
Identification of the top canonical pathways by IPKB emphasized on oxidative
stress response mediated by NRF2, 14-3-3 signaling pathway, p53 signaling pathway,
TGF- signaling pathway, etc. Transforming growth factor-β singling pathway is known
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to regulate multiple cell processes including proliferation, apoptosis, extracellular matrix
production, and differentiation (41). Literature reviews reported that an up-regulation of
TGF- signaling pathway is one of the major mechanisms that CNI nephrotoxicity
progresses into chronic condition. (41) In particular, an over-expression of this molecular
pathway causes epithelial messenchymal transition, a condition in which renal tubular
epithelial cells lose their cell morphology and acquire new characteristic features of
messenchyme, and therefore destruct basal membrane (41).
Annotation of CNI nephrotoxicity dataset when compared with normal allograft
showed synergic patterns of several important genes of TGF- signaling pathway such as
Type II receptor, TAK1, Smurf 1, GRB2, Ras, cJun, AP1, and TGIF and antagonistic
patterns of VDR and JNK, just to name a few. Genetic behavior of TGF-induced factor
homeobox 1, or TGIF1 (p=1.22E-04), was observed along with the other two potential
biomarkers (RGS1 and CXCR4) in our study because of its co-suppression activity on
smad2, an important transcription factor that, in various research studies including mouse
and human models, was believed to module fibrogenesis. In fact, interference of smad2dependent TGF-β signaling pathway causes an accumulation of extracellular matrix, the
main mechanism of renal interstitial fibrosis (58-61).
Investigation on the mechanism of action that TGIF1 involved in TGF-β signaling
pathway revealed that TGIF1 has been found to inhibit transcriptional activation by
smads but not repress TGF-β induced signals (IPA) (58,60). It was also emphasized that
upon activation, smad2 forms complex with other smad proteins and translocates to
nucleus via interaction with not only co-repressors but also co-activators (60). Although
it presented, based on microarray data of our study, a 2.132 fold change over expression
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of TGIF1 in kidney allograft diagnosed with CNI nephrotoxicity, validation step reported
TGIF1 expression level was not statistically significant emough between sample groups
to be considered as a potential gene for further study.
It has been acknowledged that long-term exposure to calcineurin inhibitor
progresses to the development of Interstitial Fibrosis and Tubular Atrophy, but the
specific insights of such disease advancing mechanism is still uncharacterized. Pair-wise
comparisons between CNI and IF/TA, with normal allograft as control, were done on the
basis of biological function analysis and toxicology profiles. Pathology of IF/TA was
characterized more with the involvement of renal necrosis and cell death as according to
the top five canonical pathway analyses compared between the two groups. Molecular
pathways that are involved in response to injury and inflammation such as NRF2mediated oxidative stress response, p-53 signaling pathway, and TGF- signaling
pathway played a less important role in the complication of IF/TA as seen in the druginduced toxicities.
Among the differentially expressed genes between the pathological groups of CNI
and IF/TA, Chemokine (C-X-C motif) receptor 4 (CXCR4, p=7.18E-05) was particularly
selected to study due to its identified interaction with cyclophilin A, which is the
ubiquitous cellular receptor of cyclosporine (62). Experimental data showed that
cyclophilin A might regulate the cascade signal events mediated by CXCR4 necessary in
T cells in various physiological and pathological conditions including human
immunodeficiency virus infection and cancer metastasis (62,63). This signal event was
terminated when cell was treated with cyclosporine A (62).
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Furthermore, in addition to its role in p38-dependent T cell apoptosis, according
to microarray analysis, CXCR4‟s significant fold change found in CNI vs. NA group
(3.328) and in IF/TA vs. NA group (21.57) indicated a computational predicted target
relationship via statistical correlation and biological significance, which can be used to
portray the progression of nephrotoxicity to chronic allograft dysfunction in kidney
tissues (63). Q-PCR validation of data only reported statistical significance of mRNA
expression level of this gene in IF/TA allograft when compared to normal allograft.
However, the significant fold changes of this gene in CNI and IF/TA groups, calculated
with results yielded from qPCR validation, might indicate that high expression level of
CXCR4 and consequence of its downstream effect could possibly a contributing factor to
the progression of CNI nephrotoxicity to IF/TA.
Initially, we were aimed to validate the identified differentially expressed genes of
this study in an independent validation set, based on an independent population of kidney
transplantation. In other words, real-time PCR was supposed to be done only on the
kidney tissues that were not been used for microarray analysis to eliminate the influence
of environmental factor as well as other factors contributed by donor‟s age, graft quality,
patient‟s health status, etc. However, we weren‟t able to find a large enough number of
kidney transplant recipients to separate the samples into considerable groups for
confirmation and validation of the microarray data. We were, instead, able to confirm and
validate the microarray data using a combined population of kidney tissues, some of
which were previously used for microarray analysis and kidney tissues that had not been
used for microarray analysis.
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As this indicated, in order to validate either diagnosis or prediction power of
RGS1 and CXCR4, future studies are necessary to prospectively assess the marker
sensitivity and specificity in a larger sample size. Research direction should consider
analyzing ontology and interaction of proposed genes in a population of kidneytransplant recipients with multiple pathologies (IF/TA, acute rejection, posttranplantation virus infection, etc.) in addition to CNI nephrotoxicity and using the aid of
appropriate statistical models. The outcome with further validation should offer the
potential of stratifying CNI nephrotoxicity to directly quantify the extent of individual
immune response toward allograft and develop more effective immunosuppresion
strategies by possibly optimizing the benefit to risk ratio of drug treatment.
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